Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

StatusUnknown
PhaseNot specified
Started

Record status This record was last updated September 19, 2024 (before its estimated December 24, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Mar 24, 2024 to Dec 24, 2024v4
  3. Primary completion date: Mar 24, 2023 to Mar 24, 2024
    • Study completion date: Mar 24, 2024 to Mar 24, 2025
    v3
  4. Primary completion date: Mar 24, 2021 to Mar 24, 2023
    • Study completion date: Mar 24, 2022 to Mar 24, 2024
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Trial Details
NCT Number NCT04324151
Lead Sponsor Hunan Province Tumor Hospital
Conditions
(from sponsor)		 Non Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov